<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792762</url>
  </required_header>
  <id_info>
    <org_study_id>H-17039726</org_study_id>
    <nct_id>NCT04792762</nct_id>
  </id_info>
  <brief_title>Physiology of GIP(1-30)NH2 in Humans</brief_title>
  <acronym>GA-11</acronym>
  <official_title>Physiology of GIP(1-30)NH2 in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucose-dependent insulinotropic polypeptide (GIP) is a gut-derived incretin hormone that&#xD;
      affects glucose, lipid and bone metabolism. Secretion of GIP into the blood stream from&#xD;
      enteroendocrine cells is stimulated bu nutrients in the gut lumen and results in potentiation&#xD;
      of glucose stimulated insulin secretion from the pancreas. The objective of this study is to&#xD;
      investigate the physiology of GIP(1-30)NH2 in humans with insulin secretion as the primary&#xD;
      endpoint. Furthermore the effects on on plasma/serum levels of glucagon, C-peptide, glucose,&#xD;
      bone markers (CTX and P1NP) will be measured.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Actual">June 9, 2019</completion_date>
  <primary_completion_date type="Actual">August 23, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin</measure>
    <time_frame>Up to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTX</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P1NP</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>GIP(1-42)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP(1-30)NH2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GIP(1-30)NH2</intervention_name>
    <description>Intravenous administration of the peptide hormone GIP(1-30)NH2 during a stepwise glucose clamp</description>
    <arm_group_label>GIP(1-30)NH2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GIP(1-42)</intervention_name>
    <description>Intravenous administration of the peptide hormone GIP(1-42) during a stepwise glucose clamp</description>
    <arm_group_label>GIP(1-42)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intravenous administration of saline during a stepwise glucose clamp</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men of Northern European descent&#xD;
&#xD;
          -  BMI: 19-25 kg/m2&#xD;
&#xD;
          -  Stable body weight (±5%) in the last three months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with medication or dietary supplements that cannot be paused for 12 hours&#xD;
&#xD;
          -  More than 14 units of alcohol per week or abuse of narcotics&#xD;
&#xD;
          -  Established liver disease and/or plasma alanine aminotransferase (ALT) ≥3 × normal&#xD;
             value and/or INR outside the normal range&#xD;
&#xD;
          -  Renal impairment (eGFR &lt;60 ml/min/1.73 m2)&#xD;
&#xD;
          -  Severe arteriosclerotic heart disease or severe heart failure (NYHA group III or IV)&#xD;
&#xD;
          -  Low blood count (haemoglobin &lt;8.3 mol/l)&#xD;
&#xD;
          -  Special diet or planned body weight change before the trial period&#xD;
&#xD;
          -  First-degree relatives with diabetes&#xD;
&#xD;
          -  Participation in other clinical experiments with medication&#xD;
&#xD;
          -  Any disease/condition that the investigators estimate disturbing for the participation&#xD;
             in the experiment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Metabolic Physiology</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 6, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

